• Questions? +1 (732) 747-1007
  • ir@americancryostem.com
  • Physicians
  • Licensing & Partners
  • SERVICES
    • HOW IT WORKS
    • COSMETIC CRYO-FAT
    • ADULT STEM CELLS
  • PRODUCTS
    • TISSUE HARVESTING SYSTEM
    • STEM CELL MEDIAS
    • STEM CELL LINES
  • OUR SCIENCE
  • INVESTORS
    • ABOUT US
    • STOCK INFORMATION
    • PRESS RELEASES
    • OUR LEADERSHIP
    • LICENSING PARTNERS
  • NEWS
  • CONTACT

American CryoStem Joins Alliance for Regenerative Medicine

February 8, 2012

RED BANK, NJ–(Marketwire – Feb 8, 2012) – American CryoStem Corporation (OTCQB: CRYO), a commercial developer, manufacturer and marketer of clinical products and services involving adipose tissue and adipose derived adult stem cells, announced its association with the Alliance for Regenerative Medicine (ARM).

ARM is a Washington, DC-based non-profit organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine. American CryoStem’s decision to join ARM was based on the alignment of its ongoing mission to offer the highest quality products and services to help accelerate the regenerative medicine industry and ARM’s support of policy efforts toward safe and reliable cellular products.

Morrie Ruffin, Managing Director for the Alliance for Regenerative Medicine, commented, “We are delighted to have American CryoStem as part of the Alliance and look forward to working together to advance the field of adipose-derived stem cells for a variety of therapeutic applications.”

ARM’s membership is diverse, representing leading regenerative medicine companies and investors, university-based and non-profit research institutions, patient advocacy groups, pharmaceutical companies engaged in regenerative medicine research and other organizations supporting regenerative medicine. American CryoStem has created and commercialized core proprietary products and platforms for processing, storing and quality management of adipose tissue and adipose derived adult stem cells that are broadly relevant to ARM’s membership.

“American CryoStem is committed to working with industry organizations to develop cutting edge adipose tissue based treatments and therapies. One unique component of our clinical laboratory product and service suite is offering individuals the opportunity to cryogenically store their younger, healthier adult stem cells for their own future use in regenerative medicine,” stated John Arnone, American CryoStem CEO. “We are pleased and honored to work with the Alliance for Regenerative Medicine to educate the public and regulators on the safe uses of adult stem cells and their potential life changing applications.”

In support of these goals, the Company recently launched ACS Laboratories, thus expanding its clinical processing technology to companies, institutions and medical professionals. ACS Laboratories offers a wide range of adipose tissue specific services. Through ACS laboratories patented ACSelerate™ cell culture media, a ten product suite, American CryoStem can leverage its technology and products to participate in a broad range of clinical application opportunities.

About American CryoStem: American CryoStem Corporation (OTCQB: CRYO) markets clinical processing products and services for adipose (fat) tissue and adipose derived adult stem cells. CRYO’s clinical processing and preservation platform supports the science and applications being discovered globally by providing the highest quality, clinically processed cells and assuring their sterility, viability and growth cap abilities, while at the same time developing cutting edge application, therapies and laboratory products and services for consumers and physicians.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the Company is detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

Share

Related posts

January 6, 2023

American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)


Read more
December 22, 2022

American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to its Advisory Board


Read more
March 4, 2022

American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)


Read more

About American CryoStem Corporation

American CryoStem Corporation (OTC:CRYO), is a clinical-stage biotechnology company, global licensor and a pioneer in autologous (one’s own) cellular processing and therapies. The Company's centralized laboratory model and patented foundational “CryoStem Platform” is a best-in-class, end-to-end cellular therapy solution to treat injuries, disorders and chronic diseases through a single adipose-tissue (fat) harvest and ATCELLBank™ cryopreservation. We are dedicated to helping the world’s physicians, hospitals, and clinics improve clinical outcomes by developing and delivering effective leading-edge stem cell therapies that improve patient health and quality of life.

© 2021 American CryoStem Corporation | A Publicly Traded Company (CRYO)
  • Physicians
  • Licensing & Partners